Analyzing the pharmacological substances and targets of Xuefu Zhuyu decoction in hypertensive vascular endothelial cells

Background:Xuefu Zhuyu decoction(XFZY)could significantly improve the function of hypertensive vascular endothelial cells,but the targets and mechanism are not clear.This study is to analyze the pharmacological substances and targets of Xuefu Zhuyu decoction in hypertensive vascular endothelial cells.Methods:This study used Xuefu Zhuyu decoction to intervene human umbilical vein endothelial cells incubated by hypertensive patients’serum,then detected the function of vascular endothelial cells.The aqueous extract of XFZY was analyzed and validated by liquid chromatography-mass spectrometry technology;Finally,macromolecular docking technology was used to analyze the potential active substances and targets of XFZY in the prevention and treatment of hypertension.Results:Compared with the model group,the XFZY group showed a significant increase in NO expression(P<0.01)and a significant decrease in ET-1 expression(P<0.001);and the expression of BIP,P-JNK,CHOP,and BAX in XFZY group cells was significantly decreased(P<0.001),while the expression of JNK and BCL2 was significantly increased(P<0.001).19 main compounds were identified in XFZY and there were 3 pairs of molecular complexes with high affinity for markers of the endoplasmic reticulum stress,including BIP-Hesperidin complex,BIP-HSYA complex and JNK-Naringin complex.Conclusion:This study analyzed the potential pharmacodynamic substance and targets of Xuefu Zhuyu decoction in improving the function of hypertensive vascular endothelial cells,which could provide a scientific basis for the future molecular mechanism of XFZY in treating hypertension.

Mechanism of the Xuefu Zhuyu decoction in treating diabetes mellitus erectile dysfunction based on the CaSR/Gq-PLC-PKC pathway

Background:To investigate the mechanism of Xuefu Zhuyu decoction in the treatment of diabetes mellitus erectile dysfunction.Methods:Rats with diabetes mellitus erectile dysfunction were developed using streptozocin and randomly assigned into model,low-dose herbal,and high-dose herbal groups.All rats were administered normal saline or the corresponding drugs by oral gavage for 4 weeks.The related indices were detected using enzyme-linked immunosorbent assays,immunohistochemistry,western blotting,and transmission electron microscopy.Results:The levels of lectin-like oxidized low-density protein receptor-1,endothelin-1,NADH oxidase,vascular cell adhesion molecule-1,and intercellular adhesion molecule-1 in the model group were significantly higher than they were in the mock group but lower than they were in the herbal treatment group.The level of nitric oxide was lower in the model group than was in the mock group but higher than the level in the herbal treatment group.The calcium-sensitive receptor,phospho-protein kinase Cδ/protein kinase Cδ,phosphorylated c-Jun amino-terminal kinase/c-Jun amino-terminal kinase,and phospho-P38 mitogen-activated protein kinase/P38 mitogen-activated protein kinase expression levels in the model group were higher than were in the mock group but lower than were in the herbal treatment group.The structures of the Corpus cavernosum penis endothelial cells were significantly improved in the herbal treatment group than they did in the model group.Conclusion:Xuefu Zhuyu decoction can decrease injury to the endothelium,improve vascular endothelial diastolic and contractive function,and inhibit vascular fibrosis in rats with diabetes mellitus erectile dysfunction.This mechanism may be related to the CaSR/Gq-PLC-PKC pathway.

The efficacy of Xuefu Zhuyu prescription for diabetic encephalopathy: A meta-analysis of randomized controlled trials

Objective:To evaluate the safety and effectiveness of Xuefu Zhuyu Decoction in treating diabetic encephalopathy.Methods:Computer search and manual search of Pub Med,Web of Science,The Cochrane Library,CNKI,WF,VIP and CBM from January 2000 to April 2020 on the treatment of diabetic encephalopathy with Xuefu Zhuyu Decoction In randomized controlled clinical trials,select documents that meet the criteria for analysis using Rev Man 5.3 software.Results:A total of 11 articles and 838 patients were included in the study.Metaanalysis showed that Xuefu Zhuyu Decoction was effective(OR=3.71,95%CI[2.42,5.70],P<0.00001),and the patient’s neurological deficit score(MD=-4.52,95%CI[-5.10,-3.94],P<0.00001),fasting blood glucose(MD=-1.05,95%CI[-1.51,-0.59],P<0.00001),2 hours postprandial blood glucose(MD=-1.31,95%CI[-1.94,-0.69],P<0.00001),glycated hemoglobin(MD=-0.94,95%CI[-1.15,-0.72],P<0.00001),TCM symptom score(MD=-2.44,95%CI[-3.82,-1.06],P=0.0005<0.01),vitality score(MD=12.79,95%CI[8.79,16.79],P<0.00001),the improvement effect is obvious Better than conventional Western medicine treatment.Conclusion:Xuefu Zhuyu Decoction can improve the clinical efficiency of patients with diabetic encephalopathy,reduce brain damage,reduce blood sugar and glycated hemoglobin levels,and has good safety.However,the quality of some of the included literatures is low,and the number of clinical cases is small,which may affect the authenticity of the Meta analysis results.Still need to be further verified by clinical randomized controlled trials with high-quality large samples.

The mechanism of Xuefu Zhuyu decoction in treating erectile dysfunction based on Arrowsmith tool

Arrowsmith,a literature retrieval tool,was used to explore the theoretical pharmacological mechanism of action of Xuefu Zhuyu decoction and its single herb against erectile dysfunction.Cytoscape 3.6.1 software was used to analyze the correlation between the components of Xuefu Zhuyu decoction and the identified mechanism of action.Different herbs in Xuefu Zhuyu decoction may play a therapeutic role by regulating iNOS,COX-2,mTOR,Wnt,AMPK,Nrf2,TLR4,CYP2D6,BDNF,MAPK,Akt,STAT3,PI3K,ERK1,P38MAPK,JNK,VEGF,and other targets.The treatment of erectile dysfunction with Xuefu Zhuyu decoction embodied the multicomponent,multitarget,and multipathway.The Arrowsmith tool retrieval and analysis provided a scientific basis for further elucidation of the mechanism of Xuefu Zhuyu decoction against erectile dysfunction.

Effects of Xuefu Zhuyu Decoction combined with conventional therapy on inflammatory response, oxidative stress, endothelium and related factors in patients with acute cerebral infarction

Objective: To explore the effects of Xuefu Zhuyu Decoction combined with conventional therapy on inflammatory response, oxidative stress, endothelium and related factors in patients with acute cerebral infarction. Methods: A total of 162 patients with acute cerebral infarction admitted to our hospital from November 2016 to January 1818 were selected as subjects. According to the random sampling method, the subjects were divided into 81 cases in the control group and 81 cases in the observation group. The control group was treated with conventional intracranial pressure, anticoagulation, anti-oxidation and lipid-lowering treatment. The observation group was treated with Xuefu Zhuyu Decoction on the basis of the control group. The changes of inflammatory response, oxidative stress, endothelium and related factors were compared and analyzed. Results:Before treatment, the levels of TNF-α, CRP, SOD, MDA, AOPPS, NO, ET-1, MMP-9, PAF and IGF-1 in the two groups were not significantly different, and there was no statistical significance. After treatment, the levels of TNF-α and CRP in the two groups were significantly lower than those before treatment, and the levels of TNF-α and CRP in the observation group were significantly lower than control group;the levels of MDA and AOPPS in the two groups were significantly lower than those before treatment, while the level of SOD was significantly higher than before treatment, and the levels of MDA and AOPPS in the observation group were significantly lower than control group, while the level of SOD was significantly higher. In the control group;the level of ET-1 in the two groups was significantly lower than that before treatment, while the level of NO was significantly higher than that before the treatment, and in the observation group the level of ET-1 was significantly lower than the control group, while the level of NO was significantly higher. In the control group;the levels of MMP-9 and PAF in the two groups were significantly lower than those before treatment, while the level of IGF-1 was significantly higher than before treatment, and the levels of MMP-9 and PAF in the observation group were significantly lower than control group, while the level of IGF-1 was significantly higher than control group. Conclusions: Xuefu Zhuyu Decoction combined with conventional treatment of acute cerebral infarction can effectively reduce inflammation and oxidative stress, improve vascular endothelial function and nerve function, and significantly reduce the degree of brain injury, which has clinical significance.

The Efficacy of Banxia Baizhu Tianma Decoction(半夏白术天麻汤)Combined with Xuefu Zhuyu Decoction(血府逐瘀汤)for Essential Hypertension and the Effects on Endothelial Function:A Systematic Review and Meta-analysis

Objective:Banxia Baizhu Tianma Decoction(半夏白术天麻汤,BBTD)combined with Xuefu Zhuyu Decoction(血府逐瘀汤,XFZYD)is widely used to treat essential hypertension in China,but its efficacy remains largely unexplored.We systemically summarized relevant evidence from randomized controlled trials(RCTs)to assess the therapeutic efficacy of BBTD+XFZYD.Methods:This review retrieved 6 databases like Pubmed,Cochrane Library,Embase,CNKI,et al.RCTs of BBTD+XFZYD plus conventional Western drugs(experimental group)and conventional Western drugs alone(control group)for hypertension was collected from the database establishment to August 5,2020.And the outcomes included clinical total effective rate,systolic blood pressure(SBP),diastolic blood pressure(DBP),nitric oxide(NO)and endothelin-1(ET-1).All studies’risk of bias were assessed by the Cochrane Collaboration tool 5.1.0.The data was statistically analyzed by RevMan5.3 Software.Results:Six studies with 608 participants were identified.About duration of treatment,4 studies were 1 month,2 studies were 2 months.The quality presented a high risk of bias.The experimental group showed that clinical total effective rate of the 1-month and 2-month was higher(P<0.00001),the systolic pressure was significantly lower(P<0.05),the NO increased(P<0.00001),and the ET-1 decreased(P<0.00001)compared with the conventional Western drugs used alone.However,DBP was significantly lower(P<0.05)at 2 months of treatment.Conclusion:BBTD+XFZYD plus conventional Western drugs might reduce blood pressure,improve clinical efficacy,repair endothelial function,but still need high-quality RCTs to better assess the outcomes.

Xuefu Zhuyu decoction improves neurological dysfunction by increasing synapsin expression after traumatic brain injury

Xuefu Zhuyu decoction has been used for treating traumatic brain injury and improving post-traumatic dysfunction, but its mechanism of action needs further investigation. This study established rat models of traumatic brain injury by controlled cortical impact. Rat models were intragastrically administered 9 and 18 g/kg Xuefu Zhuyu decoction once a day for 14 or 21 days. Changes in neurological function were assessed by modified neurological severity scores and the Morris water maze. Immunohistochemistry, western blot assay, and reverse-transcription polymerase chain reaction were used to analyze synapsin protein and m RNA expression at the injury site of rats. Our results showed that Xuefu Zhuyu decoction visibly improved neurological function of rats with traumatic brain injury. These changes were accompanied by increased expression of synaptophysin, synapsin Ⅰ, and postsynaptic density protein-95 protein and m RNA in a dose-dependent manner. These findings indicate that Xuefu Zhuyu decoction increases synapsin expression and improves neurological deficits after traumatic brain injury.

Clinical intervention effect of Xuefu Zhuyu decoction on chronic heart failure complicated with depression

BACKGROUND The diagnosis and treatment of depression in patients with chronic heart failure(CHF)is challenging,with no ideal treatment at present.AIM To analyze the clinical intervention effect of Xuefu Zhuyu decoction(XFZYD)on CHF complicated with depression.METHODS The study cohort comprised 116 patients with CHF complicated with depression who received treatment from July 2020 to July 2023,of which 55 received Western medicine(control group)and 61 received XFZYD(research group).Data on clinical effectiveness,traditional Chinese medicine(TCM)syndrome score,cardiac function,negative emotions,and serum inflammatory factors,were collected for comparative analyses.RESULTS Compared with the control group,the research group had an evidently higher total effective rate.Furthermore,there were marked reductions in TCM symptom score,left ventricular end-diastolic diameter,left ventricular end-systolic diameter,Self-Rating Depression Scale,Hamilton Depression Scale,high-sensitivity C-reactive protein,monocyte chemoattractant protein-1,and matrix metalloproteinase-9 in the research group after treatment,and these were lower than the corresponding values in the control group.Left ventricular ejection fraction was increased and higher in the research group compared with the control group after treatment.CONCLUSION Our findings conclusively proved that XFZYD was considerably superior to Western medicine for treating CHF complicated with depression because it significantly alleviated patients’symptoms,improved cardiac function,relieved negative emotions,and reduced the levels of serum inflammatory factors.

Systematic Review and Meta-analysis on the Efficacy and Safety of Xuefu Zhuyu Oral Liquid(血府逐瘀口服液)in the Treatment of Migraine

Objective:To systematically evaluate the efficacy and safety of Xuefu Zhuyu Oral Liquid(血府逐瘀口服液)in the treatment of migraine.Methods:All randomized controlled trials(RCTs)on the treatment of migraine with Xuefu Zhuyu Oral Liquid were screened out by systematically searching Cochrane Library,Pub Med,Embase,Web of Science,VIP,Wanfang,CNKI and CBM database from database establishment to March 2023.Literature screening was conducted strictly according to inclusion and exclusion criteria,and the quality of the finally included RCTs was evaluated according to the Cochrane Handbook.All data analyses were completed using Rev Man 5.4 software provided by the Cochrane Collaboration.Results:A total of 8 RCTs involving 706 patients were included.Meta-analysis showed that Xuefu Zhuyu Oral Liquid alone(RR=1.22,95%CI[1.11,1.33],P<0.0001)or combined with conventional treatment(RR=1.19,95%CI[1.11,1.28],P<0.0001)was superior to conventional treatment alone in improving the severity of headache attacks and reducing recurrence.Three studies mentioned mild adverse reactions in individual patients during the treatment process,such as transient diarrhea,lethargy,etc.,which were not directly related to Xuefu Zhuyu Oral Liquid.Conclusion:Based on the existing data and meta-analysis results,Xuefu Zhuyu Oral Liquid alone or combined with conventional treatment can improve the total effective rate of migraine treatment,alleviate headache symptoms,reduce recurrence and adverse events.In the future,large-scale and high-quality original studies are needed to further verify the efficacy and safety of Xuefu Zhuyu Oral Liquid in the treatment of migraine,and provide a reference for the clinical medication of migraine.

Identification of prototype compounds and their metabolites in rats’ serum from Xuefu Zhuyu Decoction by UPLC-Q-TOF/MS

Objective: As a classic prescription in traditional Chinese medicine, Xuefu Zhuyu Decoction(XFZYD) has been widely used in the clinical treatment of cardiovascular and cerebrovascular diseases. In order to unveil the potentially effective compounds, a rapid ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry(UPLC-Q-TOF/MS) method was established to identify prototype compounds and their metabolites from XFZYD in rats’ serum.Methods: The serum from rats after intragastric administration of XFZYD aqueous extract was analyzed by UPLC-Q-TOF/MS method. The prototype compounds and their metabolites were identified by comparison with the reference standards and tentatively characterized by comprehensively analyzing the retention time, MS data, characteristic MS fragmentation pattern and retrieving literatures.Results: A total of 175 compounds(24 prototype compounds and 151 metabolites) were identified and tentatively characterized. The metabolic pathways of prototype compounds in vivo were also summarized, including glucuronidation, hydrolyzation, sulfation, demethylation, and hydroxylation, and so on.Conclusion: In this study, a UPLC-Q-TOF/MS technique was developed to analyze prototype compounds and their metabolites from XFZYD in serum, which would provide the evidence for further studying the effective compounds of XFZYD.

血府逐瘀口服液对狼疮性肾炎患者疗效和安全性评估及血清胸腺肽β4的影响

目的探究血府逐瘀口服液(XZOL)对狼疮性肾炎(LN)患者临床疗效和安全性及血清胸腺肽β4的影响。方法纳入2021年10月至2022年10月河北北方学院附属第二医院诊治的患者为研究对象。采用随机数字表法,将LN患者分为对照组[泼尼松(PDN)+环磷酰胺(CTX)]和血府逐瘀组(XZOL联合PDN+CTX),连续治疗6个月。比较两组治疗有效率、系统性红斑狼疮疾病活动指数(SLEDAI)评分、免疫指标[抗双链DNA抗体(dsDNA)、血清免疫球蛋白(Ig)G和血清补体C3水平]、肾功能指标[血肌酐(Scr)、白蛋白(ALB)、红细胞沉降率(ESR)、谷丙转氨酶(ALT)、24 h尿蛋白和C-反应蛋白(CRP)水平]、血清胸腺肽β4水平和不良反应发生率。结果研究共纳入60例LN患者,每组各30例。血府逐瘀组治疗总有效率明显高于对照组(P<0.05)。治疗前,两组SLEDAI评分、血清胸腺肽β4、IgG、C3、抗dsDNA抗体、血清Scr、ALB、ALT、24 h尿蛋白和CRP水平差异无统计学意义(P>0.05)。治疗6个月后,两组患者SLEDAI评分、血清IgG、抗dsDNA抗体、血清Scr、ALT、24 h尿蛋白和CRP水平均较治疗前显著下降(P<0.05);而血清胸腺肽β4水平、血清C3水平和血清ALB水平显著上升(P<0.05)。且血府逐瘀组SSLEDAI评分、血清IgG、抗dsDNA抗体、血清Scr、ALT、24 h尿蛋白和CRP水平低于对照组(P<0.05);血清胸腺肽β4、C3和ALB水平高于对照组(P<0.05)。此外,两组不良反应发生率差异无统计学分析(P>0.05)。结论XZOL治疗LN临床效果显著,未见明显不良反应,值得在临床推广使用。

血府逐瘀汤联合胸腔镜手术治疗创伤性血气胸的临床疗效及对应激反应和凝血功能的影响

目的:探讨血府逐瘀汤联合胸腔镜手术治疗创伤性血气胸的临床疗效及对应激反应和凝血功能的影响。方法:将72例创伤性血气胸患者按照随机数字表法分为对照组和观察组,各36例。对照组采用胸腔镜进行手术并给予机械通气,观察组在对照组基础上联合血府逐瘀汤进行治疗。比较两组临床治疗总有效率、气滞血瘀症状评分、肺功能指标[第1秒用力呼气量(FEV1)、肺活量(VC)、最大通气量(MVV)、用力肺活量(FVC)]、应激反应指标[皮质醇(Cor)、去甲肾上腺素(NE)、胰岛素(Ins)、血管紧张素Ⅱ(AT-Ⅱ)]、凝血功能指标[凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)和D-二聚体(D-D)],以及术后并发症发生率。结果:观察组患者临床治疗总有效率为97.22%,高于对照组的83.33%,有统计学意义(P<0.05);治疗后,对照组及观察组患者气滞血瘀症状评分、Cor、NE、Ins、AT-Ⅱ、FIB水平均降低,FEV1、VC、MVV、FVC、PT、APTT、TT和D-D均升高,有统计学意义(P<0.05);与对照组比较,观察组患者气滞血瘀症状评分、Cor、NE、Ins、AT-Ⅱ、FIB水平均降低,FEV1、VC、MVV和FVC显著升高,有统计学意义(P<0.05)。结论:血府逐瘀汤联合胸腔镜手术治疗创伤性血气胸效果理想,可显著改善患者肺功能和凝血功能,减少应激反应。

血府逐瘀汤对狼疮性肾炎患者胸腺肽β4及Ea-RFC的影响

目的探讨血府逐瘀汤辅助治疗狼疮性肾炎(LN)的效果及对患者胸腺肽β4及Ea花环细胞(Ea-RFC)形成率的影响。方法选取河北北方学院附属第二医院2020年1月至2021年6月收治的60例狼疮性肾炎患者,按随机数字表法分为观察组(行血府逐瘀汤联合泼尼松与环磷酰胺治疗)30例与对照组(行泼尼松与环磷酰胺治疗)30例,治疗18个月。观察组治疗后临床效果、中医症状、胸腺肽β4表达、Ea-RFC形成率、肾功能及不良反应。结果观察组治疗总有效率为96.67%,高于对照组的80.00%,差异有统计学意义(P<0.05)。治疗后,观察组纳少腹胀、腰膝酸软、面色不华、口黏口苦等中医症状积分低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组红细胞沉降率、血清肌酐及胸腺肽β4表达低于对照组,Ea-RFC形成率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组不良反应发生率与对照组比较差异无统计学意义(P>0.05)。结论血府逐瘀汤辅助治疗LN患者疗效确切,能减少患者体内胸腺肽β4表达,提高Ea-RFC,改善肾功能,安全性较高。

血府逐瘀汤治疗冠心病研究进展

冠心病是临床常见的心血管疾病之一,其发病率和病死率呈上升趋势,严重危害居民健康,加重国家经济负担。血府逐瘀汤有活血化瘀、理气止痛的功效,主治胸中血瘀证。临床上根据其功效常用于治疗血瘀证冠心病,并取得良好疗效。此文旨在对血府逐瘀汤治疗冠心病的临床运用、作用机制及研究进展展开探讨,为深入挖掘血府逐瘀汤临床及实验研究提供新思路。

血府逐瘀汤联合腔内激光闭合术对下肢静脉曲张患者的临床疗效

目的探讨血府逐瘀汤联合腔内激光闭合术对下肢静脉曲张患者的临床疗效。方法选取2021年2月至2022年3月于河北工程大学附属医院及邯郸市中医院就诊的140例下肢静脉曲张患者,按照入院顺序编号随机分组法分为对照组(n=70,行大隐静脉高位结扎+腔内激光闭合术)与治疗组(n=70,在对照组基础上予血府逐瘀汤治疗)。比较两组患者的临床疗效,术后瘀斑、肢体疼痛、肿胀消失时间,治疗满意度及并发症发生情况。结果治疗组患者总有效率高于对照组患者,差异有统计学意义(P<0.05)。治疗组患者术后瘀斑、肢体疼痛、肢体肿胀消失时间均明显短于对照组患者,差异均有统计学意义(P<0.01)。治疗组患者治疗满意度高于对照组患者,差异有统计学意义(P<0.05)。治疗组患者并发症总发生率低于对照组患者,差异有统计学意义(P<0.05)。结论血府逐瘀汤联合腔内激光闭合术治疗下肢静脉曲张患者能够明显改善患者术后瘀斑、肢体疼痛、肿胀等症状,降低并发症发生率,提高患者的治疗满意度,临床疗效较好。

血府逐瘀汤加味联合隔药灸治疗肠粘连临床观察

目的探讨血府逐瘀汤加味联合隔药灸治疗术后肠粘连的临床效果。方法将122例术后肠粘连患者随机分为对照组和试验组,每组61例。对照组给予常规对症处理及枸橼酸莫沙必利片、颠茄片治疗,试验组在对照组基础上给予血府逐瘀汤加味联合隔药灸治疗,两组均治疗3周。比较两组临床疗效、腹痛程度评分、血清炎性细胞因子及肠道屏障功能指标水平。结果治疗后,试验组总有效率为90.16%(55/61),高于对照组的73.77%(45/61)(P<0.05)。与对照组比较,试验组治疗后疼痛分级指数(PRI)、视觉模拟量表(VAS)及现时疼痛强度(PPI)评分均较低,血清肿瘤坏死因子(TNF-α)、白细胞介素-1(IL-1)及白细胞介素-6(IL-6)水平较低,血清D-乳酸、二胺氧化酶(DAO)水平较低,谷氨酰胺(GLN)水平较高(P<0.05)。结论血府逐瘀汤加味联合隔药灸治疗术后肠粘连的临床效果显著,能明显减轻腹痛症状、抑制炎症反应、促进肠黏膜屏障功能恢复,具有临床推广应用价值。

血府逐瘀汤对人食管癌ECA-109荷瘤裸鼠肿瘤血管的影响

目的:观察血府逐瘀汤对荷瘤裸鼠肿瘤组织血管的影响。方法:采用人源食管癌细胞ECA-109构建裸鼠食管癌皮下移植瘤模型,造模后将45只裸鼠随机分为对照组和血府逐瘀汤低、高剂量组,各15只。对照组给予0.9%氯化钠溶液灌胃,血府逐瘀汤低、高剂量组分别给予1.2、4.8 g/mL血府逐瘀汤灌胃,各组连续干预14 d后剥离肿瘤组织。计算肿瘤体积及抑瘤率;通过免疫荧光法检测肿瘤血管密度、α-SMA阳性细胞覆盖率、Collegen-Ⅳ覆盖率、CD31阳性率和血管渗漏率;免疫组化法检测肿瘤组织乏氧区域面积。结果:血府逐瘀汤高、低剂量组在抑瘤率、微血管密度、α-SMA阳性细胞覆盖率、Collegen-Ⅳ覆盖率与对照组相比均显著改善(P<0.01,P<0.05),血管渗漏率及肿瘤乏氧区域面积比均低于对照组(P<0.01)。结论:血府逐瘀汤能抑制人源食管癌皮下移植瘤生长,可以改善肿瘤血管的功能和结构及肿瘤组织的乏氧状态,能一定程度促进肿瘤血管正常化。

基于网络药理学和分子对接技术探讨血府逐瘀汤“异病同治”治疗冠心病和缺血性脑卒中的作用机制

目的 通过网络药理学方法结合分子对接技术探讨血府逐瘀汤“异病同治”治疗冠心病和缺血性脑卒中的作用机制。方法 在TCMSP数据库检索并结合文献筛选血府逐瘀汤11味中药的活性成分和作用靶点,通过Uniprot数据库匹配靶点官方名称。从OMIM、DrugBank、DisGNET、TTD、GeneCards数据库获取冠心病和缺血性脑卒中相关疾病靶点,取交集靶点,构建“单味药—共有靶点—疾病”网络。建立蛋白间相互作用网络,利用Centiscape插件筛选关键靶点,利用MetaScape数据库进行GO功能分析和KEGG通路富集分析。通过AutoDockTools-1.5.6进行分子对接预测。结果 筛选后得到血府逐瘀汤活性成分192个,作用靶点394个;与冠心病和缺血性脑卒中相关且排序靠前的通路有脂质和动脉粥样硬化、缺氧诱导因子-1、松弛素、核因子-κB信号通路等,主要与脂质代谢、炎症反应、氧化应激、血管生成和细胞凋亡等生物学过程相关。本方中主要活性成分木犀草素、山柰酚、柚皮素与靶点蛋白蛋白激酶1、白蛋白、胰岛素结合较好。结论 基于网络药理学的方法发现血府逐瘀汤通过多靶点、多途径治疗冠心病和缺血性脑卒中,且多个成分表现出良好的活性;可能通过抗氧化、抗炎、抑制细胞凋亡、调节激素水平、促进血管生成等作用,改善局部缺血缺氧状态,发挥“异病同治”作用。

Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on Angiogenesis in Hindlimb Ischemic Rats

Objective:To investigate the effect and mechanism of Xuefu Zhuyu Capsule(血府逐瘀胶囊,XZC)on pro-angiogenesis in the hindlimb ischemic model rats.Methods:A total of 100 Sprague Dawley rats were randomly divided into a model group,a regular-dose XZC group(0.48 g·kg^-1·d^-1)and a high-dose XZC group(0.96 g·kg^-1·d^-1)using random number table method.The model of hindlimb ischemic rats were made through femoral artery embolization with Bletilla microsphere age nt.XZC were give n on the first day after embolization surgery and lasted 5 days.Finally 72 models were obtained with 12 in each group for each time point.The lower Ischemic limb was amputated on the third day after embolization surgery.Histopathological characters and the number of blood vessels of granulation tissues were observed at 36 and 48 h after amputation,respectively.The main genes were obtained from microarray analysis and were validated using real-time quarttitative polymerase chain reaction.Results:The vascular number of granulation tissues at both 36 and 48 h were characterized by new and fresh vessels.The number of angiogenesis in the high-dose XZC group at 36 and 48 h was greater compared with that in the regular-dose XZC and model groups(P<0.01),and high-dose XZC at 36 h increased more vessels than that at 48 h(P<0.01).Consequently,granulation tissues from the high-dose XZC group at 36 h were chosen for microarray analysis.In all,2,085 differentially expressed genes(DEGs)were detected and 25 DEGs were determined to be directly related to an giogenesis.Four biological process terms were found including an giogenesis,regulati on of an gioge nesis,positive regulati on of an giogenesis,and positive regulation of vascular end othelial growth factor receptor sign aling pathway(P<0.05).Microarray an alysis also showed 49 pathways including 11 pathways related to an giogenesis.Conclusion:XZC promoted angiogenesis moderately and the mechanism invoIved multiple DEGs and multiple pathways.

血府逐瘀汤及其加减方治疗冠状动脉粥样硬化性心脏病临床研究进展

血府逐瘀汤由桃仁、红花、川芎、牛膝、赤芍、当归、生地、桔梗、枳壳、柴胡、甘草组成,具有活血化瘀、行气止痛的功效,是众多医家推崇的治疗胸痹心痛病的经典方剂。现代临床应用中,血府逐瘀汤原方及其加减方均可用于治疗冠心病,并能与西药、中药、特色疗法联合应用。临床疗效显示,血府逐瘀汤及其加减方能够明显缓解患者胸闷、憋气等不适症状,提高患者生活质量,并减少不良反应的发生。药理学实验证明,血府逐瘀汤可通过减轻血管炎性活动、优化内皮细胞功能、改善血脂代谢、抑制血小板聚集、抗心肌缺血等途径发挥治疗效果,其有效活性成分如β-谷甾醇、槲皮素等也可起到消炎、抗血小板、调节脂质代谢等作用。对血府逐瘀汤治疗冠心病的临床应用和基础研究进展进行系统综述。